Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

SMS

- PMLiVE

Experts issue call for new ‘toolbox’ to simplify early-phase clinical trial regulation in UK

The article outlines several recommendations to help improve early-phase clinical trials

- PMLiVE

Researchers identify new major cause of inflammatory bowel disease

Crohn’s disease and ulcerative colitis affected more than 500,000 people in the UK in 2022

- PMLiVE

GSK becomes first founding partner of global initiative tackling antimicrobial resistance

AMR could cause an estimated ten million deaths every year by 2050 unless action is taken

- PMLiVE

UK scientists discover two genes offering potential drug targets against skin cancer

The three major types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma

- PMLiVE

Scientists recommend new imaging technique to support design of innovative cancer drugs

Cryo-EM helped to determine the detailed structures of CAK, a promising target for cancer drugs

- PMLiVE

First UK cancer patients receive Moderna’s experimental mRNA therapy

The Mobilize trial is evaluating mRNA-4359 in cancers including melanoma and lung cancer

- PMLiVE

Study reveals T cells could provide more protection against Omicron in future vaccines

Memory T cells were found to be more effective at fighting SARS-CoV-2 than antibodies

- PMLiVE

Study suggests simple blood test could spare brain cancer patients risky surgery

The TriNetra-Glio test isolates broken-free tumour cells from the circulating tumour in the blood

- PMLiVE

Testing antibodies in blood samples could help prevent heart attacks

People with serious atherosclerosis are more likely to have a serious heart or circulatory problem

- PMLiVE

‘Click chemistry’ system used to map new class of drug targets in cancer and immunology

The novel tagging system won the Nobel Prize in Chemistry in October 2022

- PMLiVE

Study suggests self-reported information could help predict MS progression

Predicting MS progression could improve treatment and care outcomes for patients

- PMLiVE

Crick Institute announces new molecular glue discovery to treat different diseases

The £11.2m research investment includes funds from AstraZeneca and the EPSRC

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links